List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
IN NOVEMBER 2017, leadXpro chose to strengthen its capabilities with the Creoptix™ WAVEsystem. “We were looking for a label‑free, biophysical method to investigate binding affinity and kinetics of small molecules with challenging integral membrane proteins,” explained Michael Hennig, Chief Executive Officer of leadXpro.
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures, stem cells and CRISPR-based screens can lead to the next generation of therapeutics.
The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to be the testing systems used, particularly two-dimensional (2D) monolayer assay formats, which are the traditional mainstay of high-throughput compound screening.
This application note by ForteBio explores antibody fragment molecule (Fab) for process development and quality control.
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
So you have performed your screen. What’s next? This guide is focused on how biochemical assays are used for characterising and prioritising compounds.
4 September 2020 | By Horizon Discovery
During this on-demand webinar we present data showing how Horizon’s CRISPRsc screening platform offers a streamlined approach to elucidating valuable and intriguing biological information that is critical to resolving complex biological questions.
A compound called BOLD-100, which has shown efficacy against COVID-19 in pre-clinical trials, has now outperformed remdesivir in a cytopathic effect assay.
HCPs are critical to quality control in biologics development. If left unremoved, they can cause immunogenic responses and reduce drug efficacy.
Tested on two assays, researchers have shown that Redx03863 and Redx04739 can combat tuberculosis and do not lead to resistance.
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
